A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Purpose

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

Condition

  • Pneumonia

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion - Acute hypoxemic respiratory failure (AHRF) - Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria - Onset of severe pneumonia with AHRF ≤7 days prior to informed consent

Exclusion Criteria

  • More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent - Pregnancy or breastfeeding - History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative - Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor Note: Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
The Run-in Phase is open label and non-randomized, Phase 2 is double blind and randomized.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
agenT-797 plus SOC 		Participants will receive agenT-797 and SOC.
  • Drug: agenT-797
    Intravenous infusion
  • Drug: Standard of Care (SOC)
    Antimicrobial therapy and corticosteroids per applicable guidelines.
Placebo Comparator
Placebo plus SOC 		Participants will receive placebo and SOC.
  • Drug: Placebo
    Intravenous infusion
  • Drug: Standard of Care (SOC)
    Antimicrobial therapy and corticosteroids per applicable guidelines.

More Details

Status
Recruiting
Sponsor
MiNK Therapeutics

Study Contact

MiNK Therapeutics Clinical Trial Information
1-212-994-8250
webmaster@minktherapeutics.com

Detailed Description

This trial will be conducted in 2 parts (Run-in Phase; Phase 2). The Run-in Phase is designed to characterize the baseline population of the site, where participants will receive open-label agenT-797 plus SOC. After completion of the Run-in Phase, participants will be enrolled and randomized to receive either agenT-797 plus SOC or placebo plus SOC during the double-blinded Phase 2.